Home Featured Page 199

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent...

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for...

Eyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and...

Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience

Psychedelic Bypassing: When Avoidance is Mistaken for Healing

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

The Serotonin 5-HT2A Receptor: From Mice to Humans

CaaMTech Teams Up With University of Wyoming to Study Psychedelics as...

1...198199200...296 Page 199 of 296

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

Wesana Health Clinics Surpass 4,000 Administered Ketamine Treatments

MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent...

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for...

Eyes on Oregon, a Psychedelics Today Podcast with Jon Dennis and...

Filament Health Announces Co-Development and Exclusive Licensing Agreement with Entheotech Bioscience

Psychedelic Bypassing: When Avoidance is Mistaken for Healing

MYND Diagnostics Commences Clinical Research on Alzheimer’s Disease

The Serotonin 5-HT2A Receptor: From Mice to Humans

CaaMTech Teams Up With University of Wyoming to Study Psychedelics as...

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY